Strona główna・Stock List・Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc

Open

SectorHealthcare

14.93 2.47

Buy Sell

Overview

Share price change

24h

Current

Min

14.47

Max

14.8

Key metrics
By Trading Economics
Income	-176M 34M
Sales	591K 78M
P/E Sector Avg	7.112 64.641
EPS	0.25
Profit margin	44.212
Employees	128
EBITDA	2.7M 50M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+7.55% upside

Dividends
By Acuity
Next Earnings	6 sie 2026

Market Stats
By TradingEconomics
Market Cap	-92M 2B
Previous open	12.46
Previous close	14.93

News Sentiment

By Acuity

50%

151 / 340 Ranking in Healthcare

Aurinia Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 sie 2026, 22:01 UTC

Aurinia Pharmaceuticals shares are higher in after-market hours, despite being below the 20-day moving average and three prior lower daily closes.

1 sie 2026, 00:01 UTC

Aurinia Pharmaceuticals Inc is trading lower in after-market hours, reflecting a significant decline in the overall market and ongoing weakness in performance metrics.

31 lip 2026, 21:01 UTC

Aurinia Pharmaceuticals Inc is higher in after-market trading, rising notably from a flat start. The stock remains below its 20-day moving average.

30 lip 2026, 20:31 UTC

Aurinia Pharmaceuticals Inc. shares rose in after-market trading, following a broader market trend as the S&P 500 also gained. No specific news was identified.

29 lip 2026, 22:01 UTC

Aurinia Pharmaceuticals Inc shares are lower in after-market hours, showing notable weakness and trading below its 20-day moving average. No specific news was identified.

28 lip 2026, 19:36 UTC

Aurinia Pharmaceuticals shares are lower, reflecting volatility amid broader market conditions. The stock is trading significantly below its 20-day moving average.

27 lip 2026, 19:16 UTC

Aurinia Pharmaceuticals is trading higher, benefiting from lower oil prices and easing inflation concerns ahead of the Federal Reserve meeting later this week.

24 lip 2026, 18:26 UTC

Aurinia Pharmaceuticals is trading higher, despite pulling back from earlier gains. Broader market volatility, influenced by declining oil prices, impacts sentiment.

22 lip 2026, 19:46 UTC

Aurinia Pharmaceuticals shares are lower today, continuing a decline since Tuesday's close. The stock is near its one-month trading range's lower end.

21 lip 2026, 19:16 UTC

Aurinia Pharmaceuticals is higher today, supported by a broader market uptick as investor interest in AI-related stocks grows ahead of major tech earnings.

20 lip 2026, 20:01 UTC

Aurinia Pharmaceuticals is lower today, reflecting broader market declines amid geopolitical tensions and oil price fluctuations. The stock hit a session low earlier.

Peer Comparison

Price change

Aurinia Pharmaceuticals Inc Forecast

Price Target

By TipRanks

7.55% upside

12 Months Forecast

Average 15.67 USD 7.55%

High 17 USD

Low 15 USD

Based on 3 Wall Street analysts offering 12 month price targets forAurinia Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Aurinia Pharmaceuticals Inc - Dist in the past 3 months.

Sentiment

By Acuity

151 / 340 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.